ArticleAddictive behaviors reports2022
Use of plant-based hallucinogens and dissociative agents: U.S. Time Trends, 2002-2019.
Article in Addictive behaviors reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Interpol review of forensic drug chemistry, 2022-2025.Forensic science international. Synergy · 2026Review
- Changes over time in hallucinogen-related emergency department visits in Ontario, Canada.Addiction (Abingdon, England) · 2026Article
- Hallucinogen use in the United States, 2021-2023: Diverging trends and subgroup patterns.Drug and alcohol dependence reports · 2026Article
- Cannabis and Psychedelics Among U.S. Young Adults: Use, Messaging Exposure, Perceptions, and Legalization Support.International journal of environmental research and public health · 2026Article
- Grayken lessons: a multidisciplinary approach to care for a patient with severe ketamine use disorder.Addiction science & clinical practice · 2026Article
- Level of preparedness to use psilocybin among individuals seeking psychedelic risk reduction: a retrospective study of a pilot psychiatric consultation service.Frontiers in public health · 2026Article
- Priorities for public health preparedness for psychedelics: education, workforce readiness, and strategic information needs in a rapidly changing landscape.Frontiers in public health · 2026Article
- Trends in Hallucinogen-Related Emergency Department and Hospital Admissions, 2016 to 2023.JAMA network open · 2025Article
- Do undergraduates' views of psychedelics relate to the context for psychedelic use?Drug science, policy and law · 2025Article
- Trends in ketamine use among nightclub attendees in New York City, 2017-2024.The International journal on drug policy · 2025Article
- Trends and characteristics in ketamine use among US adults with and without depression, 2015-2022.Journal of affective disorders · 2025Article
- Crafting effective regulatory policies for psychedelics: What can be learned from the case of cannabis?Addiction (Abingdon, England) · 2025Article
- Geographical Differences in Self-Reported Past 12-Month Drug Use: Results from the NDEWS Rapid Street Reporting, 2021-2023.Substance use & misuse · 2025Article
- Article
- National and regional trends in seizures of shrooms (psilocybin) in the United States, 2017-2022.Drug and alcohol dependence · 2024Article
- Review
- Trends in drug use among nightclub and festival attendees in New York City, 2017-2022.The International journal on drug policy · 2023Article
- Seasonal Variation of Use of Common Psychedelics and Party Drugs Among Nightclub/Festival Attendees in New York City.Journal of psychoactive drugsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
Aims: Information on time trends in use of different plant-based hallucinogens is lacking. The current study used nationally representative U.S. data to assess overall and age-specific time trends in the prevalence of lifetime and 12-month use of plant-based hallucinogens and dissociative agents. Methods: Participants were respondents aged ≥ 12 years (N = 1,006,051) from the National Survey on Drug Use and Health, 2002-2019. Predictors were continuous years. Outcomes included illicit use of peyote, mescaline, psilocybin, ketamine, salvia, and tryptamine. Sociodemographic variables (gender; age; race/ethnicity; educational level; family income) were modeled as covariates. Trends were estimated overall and by age (12-17, 18-25, 26+). Prevalence differences [PDs] were obtained for each category, along with 95 % confidence intervals [CI]. Results: Increases in lifetime use were observed for psilocybin (2002-2019 PD=+1.61), tryptamine (2006-2014 PD=+0.55; 2015-2019 PD=+0.44), and ketamine (2006-2014 PD=+0.27; 2015-2019 PD=+0.21). Mescaline use decreased (PD = -0.89). While overall lifetime salvia use increased between 2006 and 2014 (PD=+1.81), prevalence did not change between 2015 and 2019. Twelve-month use of tryptamine and ketamine increased between 2006 and 2014 (PD=+0.14; +0.03, respectively). Twelve-month ketamine use also increased from 2015 to 2019 (PD=+0.03). By age, participants aged 12-17 and 18-25 showed decreases in use of most types of hallucinogens, but those age 26+ generally showed increases. Conclusions: While use of plant-based hallucinogens and dissociative agents remains rare, lifetime use of ketamine, tryptamine, and psilocybin is increasing in adults. Considering these increases alongside concerns about unsupervised use of illicit products whose dose and composition is uncertain, clinicians and policymakers should remain mindful of the rising rates of illicit use in the general population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.